Analysts expect Zafgen, Inc. (NASDAQ:ZFGN) to report $-0.59 EPS on March, 8.They anticipate $0.21 EPS change or 55.26% from last quarter’s $-0.38 EPS. After having $-0.46 EPS previously, Zafgen, Inc.’s analysts see 28.26% EPS growth. The stock decreased 3.07% or $0.25 during the last trading session, reaching $7.81. About 171,188 shares traded or 12.00% up from the average. Zafgen, Inc. (NASDAQ:ZFGN) has declined 36.39% since February 9, 2017 and is downtrending. It has underperformed by 53.09% the S&P500.
Capital World Investors increased Hologic Inc (HOLX) stake by 117.65% reported in 2017Q3 SEC filing. Capital World Investors acquired 8.10 million shares as Hologic Inc (HOLX)’s stock rose 7.50%. The Capital World Investors holds 14.99M shares with $549.80 million value, up from 6.89M last quarter. Hologic Inc now has $10.49 billion valuation. The stock decreased 6.47% or $2.51 during the last trading session, reaching $36.29. About 3.72 million shares traded or 32.97% up from the average. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since February 9, 2017 and is uptrending. It has outperformed by 12.51% the S&P500.
Among 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Zafgen Inc had 18 analyst reports since August 25, 2015 according to SRatingsIntel. As per Thursday, October 15, the company rating was maintained by FBR Capital. The stock of Zafgen, Inc. (NASDAQ:ZFGN) earned “Mkt Perform” rating by FBR Capital on Wednesday, July 20. The rating was downgraded by SunTrust to “Neutral” on Thursday, December 3. Cowen & Co maintained the stock with “Buy” rating in Tuesday, August 25 report. The rating was upgraded by RBC Capital Markets to “Outperform” on Thursday, January 21. The company was maintained on Thursday, October 15 by RBC Capital Markets. The stock has “Sector Perform” rating by RBC Capital Markets on Wednesday, December 2. On Thursday, January 21 the stock rating was upgraded by FBR Capital to “Outperform”. The stock has “Hold” rating by Canaccord Genuity on Thursday, March 10. On Wednesday, July 20 the stock rating was downgraded by Cowen & Co to “Market Perform”.
Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company has market cap of $214.77 million. The company's lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. It currently has negative earnings.
Capital World Investors decreased Incyte Corp (NASDAQ:INCY) stake by 83,925 shares to 6.70M valued at $782.52 million in 2017Q3. It also reduced Paychex Inc (NASDAQ:PAYX) stake by 317,800 shares and now owns 4.10 million shares. Northrop Grumman Corp (NYSE:NOC) was reduced too.
Among 17 analysts covering Hologic (NASDAQ:HOLX), 13 have Buy rating, 0 Sell and 4 Hold. Therefore 76% are positive. Hologic had 53 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was upgraded by Barclays Capital on Wednesday, September 2 to “Equal Weight”. As per Friday, February 9, the company rating was maintained by Cowen & Co. The firm earned “Buy” rating on Monday, August 3 by Argus Research. The firm earned “Hold” rating on Friday, February 9 by Stifel Nicolaus. The stock has “Buy” rating by Jefferies on Tuesday, June 27. Evercore downgraded Hologic, Inc. (NASDAQ:HOLX) on Wednesday, January 4 to “Hold” rating. The company was upgraded on Wednesday, December 20 by Cowen & Co. The rating was upgraded by Bank of America on Thursday, January 4 to “Buy”. On Friday, February 9 the stock rating was maintained by Needham with “Buy”. The firm has “Neutral” rating by Bank of America given on Wednesday, February 15.